Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986698 · ClinicalTrials.gov registry record · Phase 1
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02986698: Clinical Trial Phase 1 study, sponsored by University of California, San Francisco.
NCT02986698 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02986698, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
Primary Outcome
Maternal participant tolerance of bone marrow harvest defined as not requiring interventions for preterm labor, bleeding, infection or prolonged hospitalization.
Interventions
- BIOLOGICAL in utero hematopoietic stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Why NCT02986698 stopped before completion
NCT02986698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which in utero hematopoietic stem cell transplantation is the first listed.
NCT02986698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02986698 about?
NCT02986698 is a clinical study titled "In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)". The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
What is the current status of trial NCT02986698?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-10-05. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT02986698?
The interventions under investigation include: in utero hematopoietic stem cell transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT02986698?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02986698's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI